Multiple presentations on nab-driven chemotherapy at 46th ASCO

[News]

Abraxis BioScience, Inc. presented abstracts describing 10 trials of nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension), for the treatment of breast cancer at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

More... (http://www.news-medical.net/news/20100609/Multiple-presentations-on-nab-driven-chemotherapy-at-46th-ASCO.aspx)